43538-550 : Loprox 7.7 mg/ml Topical Suspension


NDC43538-550
Labeler: Medimetriks Pharmaceuticals, Inc.
Product Type: Human Prescription Drug
Drug Name:  Loprox
Dosage Form: Topical Suspension
Application #: NDA019824
Rev. Date: 


NDC Package Codes:

  • 43538-550-60: 1 BOTTLE IN 1 CARTON (43538‑550‑60) > 60 ML IN 1 BOTTLE

Active Ingredients:

  • Ciclopirox Olamine

Dosage Strength:

  • 7.7 mg/mL

Pharmaceutical Classes:

  • Decreased DNA Replication [PE]
  • Decreased Protein Synthesis [PE]
  • Decreased RNA Replication [PE]
  • Protein Synthesis Inhibitors [MoA]

Related Products:

Based on records with the same trade name.
  • 43538-540 Loprox 7.7 mg/g Topical Cream by Medimetriks Pharmaceuticals, Inc.
  • 43538-541 Loprox Kit by Medimetriks Pharmaceuticals, Inc.
  • 43538-551 Loprox Kit by Medimetriks Pharmaceuticals, Inc.
  • 99207-010 Loprox 10 mg/.96ml Topical Shampoo by Medicis Pharmaceutical Corp

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 43538-550 QR Code

< Prev: 43538-541Next: 43538-551 >

Related Discussions:

side effects ciclopirox
side effects ciclopirox use ## Possible Side Effects for Ciclopirox (Topical): "Some side effects may occur that usu... 1 reply
loprox gel
dermotology use ## How is Loprox going to change my nail and the disconnected nail bed? ## Loprox contains the active in... 2 replies
loprox cream
for dermatologic use ## It contains the active ingredient Ciclopirox and it is used to treat fungal infections, such as ... 1 reply
ciclopirox olamine
topical cream/ointment ## Information in box was not comprehensive enough. Had to go to internet to get the whole story.... 1 reply




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.